Post Marketing Study on Pluvicto in Korea

Sponsor
Novartis Pharmaceuticals
Study ID
NCT06514521
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
MALE
Age
18 Years - 100 Years
Healthy Volunteers
Not accepted

Interventions

  • Lutetium vipivotide tetraxetan — OTHER
    This is an observational study. There is no treatment allocation. The decision to initiate Lutetium vipivotide tetraxetan will be based solely on clinical judgement.

Study Details

Post marketing study on Pluvicto in Korea

Key Dates

First listed
Jul 23, 2024
Start date
Apr 18, 2025
Status verified
Jun 2026
Primary completion
May 31, 2028
Completion
May 31, 2028

Study Design

Enrollment
278 participants (estimated)

Arms

  • Arm: Lutetium vipivotide tetraxetan
    Patients prescribed with Lutetium vipivotide tetraxetan in real world practice

Primary Outcome Measure

Incidence of Adverse Events, Serious Adverse Events, unexpected Adverse Events, Adverse Drug Reactions, Serious Adverse Drug Reactions and unexpected Adverse Drug Reactions [ Time Frame: Until 30 days after the last dose of Pluvicto, up to 33 months ]

Central Contacts

Find similar trials

Nationwide
Prostate cancer trialsOncology trialsProstate oncology trialsMen's health trialsUrology trials

Related Studies